Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Liposomes × Clear all
NCT00761644 2019-04-11

Doxil, Bevacizumab and Temsirolimus Trial

M.D. Anderson Cancer Center

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡